SCHEMBL2468019

SCHEMBL2468019

COc1ccc(CCC(=O)CC(CC(C)=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.60
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
MAOA P21397 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A3 Q01959 1/20 0.48
FFAR1 O14842 3/20 0.47
POLB P06746 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5574507 0.85 TRPV1 (0.51) F2RL1ALDH1A1KDM4ELMNATP53
SCHEMBL11635782 0.81 ALDH1A1 (0.56) ALDH1A1L3MBTL1NPC1RAB9AKDM4E
SCHEMBL4295436 0.80 F2RL1 (0.70) F2RL1ALDH1A1L3MBTL1SMN1; SMN2NPC1
SCHEMBL7329940 0.79 F2RL1 (0.85) F2RL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL24799818 0.79 F2RL1 (0.72) F2RL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL19520499 0.79 F2RL1 (0.83) F2RL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL1334 0.78 SMN1; SMN2 (0.72) F2RL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2468017 0.78 SMN1; SMN2 (0.72) F2RL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL17521558 0.77 L3MBTL1 (0.52) ALDH1A1L3MBTL1NPC1KDM4EMAPT
SCHEMBL22036296 0.77 F2RL1 (0.64) F2RL1ALDH1A1L3MBTL1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2555763-A1 VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT Cesa Alliance S.A. (LU) 2013-02-13 EP disclosed
WO-2011117424-A1 VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT CESA ALLIANCE S.A. (LU) 2011-09-29 WO disclosed